Evidence map›Paper›PMID 38948014›Full record

Trial reportTremor and other hyperkinetic movements (New York, N.Y.)2024

Incobotulinum Toxin-A in Professional Musicians with Focal Task-Specific Dystonia: A Double Blind, Placebo Controlled, Cross-Over Study.

Steven J Frucht, Mary Catherine George, Alexander Pantelyat, Eckart Altenmueller, Alexandra Nmashie, Jocelyn M Jiao, Michael Chen, David Feng, Susan Shin, Michelle C Kaku and 1 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Tremor and other hyperkinetic movements (New York, N.Y.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Observational
  4. Divergent Recovery Paths in Musicians' Dystonia.Tremor and other hyperkinetic movements (New York, N.Y.) · 2026
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Steven J Frucht *New York University Grossman School of Medicine, US.
Mary Catherine GeorgeIcahn School of Medicine at Mount Sinai, US.
Alexander PantelyatJohns Hopkins School of Medicine, US.
Eckart AltenmuellerInstitute of Music Physiology and Musicians' Medicine of the University of Music, Drama and Media, Hannover, DE.
Alexandra NmashieDepartment of Pediatrics, New York Medical College, US.
Jocelyn M JiaoStanford University School of Medicine, US.
Michael ChenIcahn School of Medicine at Mount Sinai, US.
David FengIcahn School of Medicine at Mount Sinai, US.
Susan ShinIcahn School of Medicine at Mount Sinai, US.
Michelle C KakuIcahn School of Medicine at Mount Sinai, US.
David Simpson *Icahn School of Medicine at Mount Sinai, US.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Musician's focal task-specific dystonia is a complex disorder of fine motor control, with incomplete understanding of its etiology. There have been relatively few trials of botulinum toxin in upper limb task-specific dystonia, and prior studies have yielded variable results, leading to skepticism regarding the utility of this approach in elite performers. Methods: We conducted a double-blind, placebo-controlled, randomized, cross-over study of incobotulinum toxin-A in 21 professional musicians with focal upper extremity task-specific dystonia affecting performance on their instrument, using a novel paradigm of initial injections followed by booster injections at two- and four-week intervals. The primary outcome measure was the change in blinded dystonia rating of the active arm by two expert raters using a Clinical Global Impression numeric scale at week 8 compared to enrollment. Findings: 19 men and 2 women with musicians' dystonia were enrolled over a six-year period. Nineteen patients completed the study. Analysis of the primary outcome measure in comparison to baseline revealed a change in dystonia severity of P = 0.04 and an improvement in overall musical performance of P = 0.027. No clinically significant weakness was observed, and neutralizing antibodies to toxin were not found. Interpretation: Despite its small sample size, our study demonstrated a statistically significant benefit of incobotulinum toxin-A injections as a treatment for musicians' task-specific dystonia. Tailoring the use of toxin with booster injections allowed refinement of dosing strategy and outcomes, with benefits that were meaningful to patients clearly visible on videotaped evaluations. In addition to its application to musicians' dystonia, this approach may have relevance to optimize application of botulinum toxin in other forms of focal dystonia such as blepharospasm, cervical dystonia, writer's cramp, and spasmodic dysphonia.

Indexed as

Botulinum Toxins, Type ACross-Over StudiesDystonic DisordersMusicNeuromuscular AgentsAdultDouble-Blind MethodFemaleHumansMaleMiddle AgedOccupational DiseasesTreatment OutcomeBotulinum Toxins, Type AincobotulinumtoxinANeuromuscular Agentsbooster dosedystoniaincobotulinum toxinmusician

Identifiers

PMID38948014
PMCPMC11212776

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.